Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07452094 · ClinicalTrials.gov registry record · Early Phase 1
What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?
A Early Phase 1 study, sponsored by Northern Arizona University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT07452094 is a Early Phase 1 study that has not yet begun recruiting, run by Northern Arizona University. The registered enrollment target is 15 participants.
The verdict
NCT07452094, a Early Phase 1 study, has not yet begun recruiting, sponsored by Northern Arizona University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. These responses must be proportional to the increase in demand and some signal must relay information from the muscle to the brain. Group III/IV afferents do just this. They relay information about the muscle (movement, temperature, acidity, etc.) up to the brain so that appropriate responses are mounted. There is strong evidence in animals that group III/IV afferents play a key role in making breathing easier (decreasing airway resistance) and initiating sweating and blood flow responses. There has been no research on the role of group III/IV afferents on these fundamental exercise responses in humans. The investigators propose to isolate the role of group III/IV afferents on regulate airway resistance, sweating and blood flow responses to exercise in humans.
Interventions
- DRUG EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2027-04-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07452094
The ClinicalTrials.gov registry entry for NCT07452094 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northern Arizona University, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EXERCISE TRAINING WITH OR WITHOUT MEDICATION is the first listed.
NCT07452094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07452094 about?
NCT07452094 is a clinical study titled "What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?". Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. Th...
What is the current status of trial NCT07452094?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2026-04-01. Estimated completion is 2027-04-01.
What interventions are being tested in trial NCT07452094?
The interventions under investigation include: EXERCISE TRAINING WITH OR WITHOUT MEDICATION (DRUG).
Who is sponsoring clinical trial NCT07452094?
This trial is sponsored by Northern Arizona University, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.